Findings from City University of Hong Kong Update Knowledge of LymphomaHispanicBusiness.comNext, under the guidance of ROR1 fluorescence, the rituximab-conjugated AFM tips were moved to cancer cells to image the cellular morphologies and detect the CD2…
|
New Stem Cells Findings from Temple University Discussed
HispanicBusiness.com MethodsWe treated 397 patients who had disease with an age-adjusted classification of high risk or high-intermediate risk with five cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP plus rituximab.” Our news … |
MedscapeBiologicals Improve RA Function More Than Other DMARDsMedscapeThe trials included abatacept, adalimumab, certolizumab, etanercept, golimumab, infliximab, or rituximab compared with either nbDMARDs or placebo. The main outcome measure was improv…
|
Cell Therapeutics Reaches Pricing Agreement in Germany
Drug Discovery & Development CTI is currently accruing patients into a Phase 3 trial comparing Pixuvri and rituximab with gemcitabine and rituximab in the setting of aggressive B-cell NHL. Pixuvri does not have marketing approval in the United States. Date: December 4, 2013 … |
Medical Marketing and Media |
Celgene buys into anticancer antibodies
Chemistry World US firms Celgene and OncoMed have tied up a deal to develop and commercialise biological therapies for cancer. The deal gives Celgene access to six antibody products in OncoMed’s pipeline, designed to target cancer stem cells rather than regular tumour … Who Benefits From the OncoMed and Celgene Partnership?Motley Fool Celgene Plunks Down $177M Upfront for OncoMed’s Stem Cell DrugsXconomy Celgene, OncoMed in $177M Cancer Stem Cell…PharmaLive (press release) (subscription) GlobeNewswire (press release) all 94 news articles » |
PR Web (press release)Monoclonal Antibodies Market in Breast Cancer to 2019PR Web (press release)MarketResearch.com announces the addition of a new market research report to their product offering: Monoclonal Antibodies Market in Breast Cancer to 2019 …
|
Monoclonal Antibodies Market in Breast Cancer to 2019
DigitalJournal.com GBI Research has released the pharmaceutical report “Monoclonal Antibodies Market in Breast Cancer to 2019 – Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth”. The current market for breast cancer consists of five monoclonal … |
|
Cell Therapeutics and GKV-SV Reach Agreement on Pricing of PIXUVRI …
MarketWatch The European Medicines Agency’s (the “EMA”) Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled Phase 3 clinical trial, which compares PIXUVRI-rituximab to gemcitabine-rituximab in patients who … |
Medscape |
Sjögren Syndrome: An A-to-Z Update
Medscape Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome. Ann Rheum Dis. 2007;66:351-357. Abstract. Bowman SJ, Fox RI. Classification criteria for Sjogren’s … |
Combination regimen effective in DLBCL with cardiac comorbidityHealioCombination treatment with rituximab, cyclophosphamide, vincristine, gemcitabine and prednisolone appeared active and tolerable in patients with diffuse large B-cell lymphoma who are …